Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Breast Cancer Research

Fig. 3

From: Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association

Fig. 3

GR liganding alters genome-wide ER chromatin association including disruption of ER chromatin occupancy at CCND1, CDK2, and CDK6 enhancer regions. a MCF-7 cells were treated with vehicle (ETOH), 100 nM Dex, 100 nM E2, or co-treated with Dex/E2 followed by ER ChIP-seq. There were n = 16,181 ER peaks lost and 10,265 ER peaks gained with Dex/E2 co-treatment, while only 2637 ER peaks were conserved when compared to ER peaks following E2-treatment alone. b E2-treated cells revealed ER peaks in previously established ER enhancer regions of CCND1 [21], CDK2 [36], and CDK6 [36] as indicated in red. c Motif analyses identified a predominance of FOXA1 (dark gray) response elements (REs) and GREs (light gray) in these ER enhancer regions. d Directed GR ChIP of MCF-7 cells treated with GR ligands for either 15, 30, or 60 min revealed consistent GR occupancy at known ER enhancer regions (CCND1, CDK2, and CDK6) following GR ligand treatment. e Following directed ER ChIP, ER enrichment at the CCND1, CDK2, and CDK6 enhancer sites was uniformly suppressed with the addition of GR ligands

Back to article page